Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The μ-opioid receptor and treatment response to naltrexone.

Alcohol and alcoholism (Oxford, Oxfordshire) - 1 Jan 2000

Thorsell Annika

Abstract excerpt

AIMS: To evaluate the pharmacogenetic evidence relating to the use of opioid antagonists (in particular naltrexone) in treating patients with alcohol abuse problems. METHODS: Narrative review of pre-clinical and clinical published research regarding genetic modulation of psychotropic effects produced by alcohol and the therapeutic effects of opioid antagonists. RESULTS: Alcohol activates brain reward pathways,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Behavior, Addictive
Share to OPRM1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Naltrexone

Share to Narcotic Antagonists

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Share to Reward

Source

Identifiers

PMID: 23543091
DOI: 10.1093/alcalc/agt030

Genes

OPRM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The μ-opioid receptor and treatment response to naltrexone.PMID 23543091Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.Semantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: alcohol and opiates.Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.Semantic proximity Read ↗

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Semantic proximity Read ↗

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.